...return. Bunting also cited the return on Abingworth's 2003 seed investment of $2.2 million in Ribopharma AG... ...deal for an undisclosed amount. "We knew that Alnylam would be forced to merge with Ribopharma... ...it had the top IP- the most important patents in the space were held by Ribopharma...
...Alnylam business unit Ribopharma AG (Kulmbach, Germany) licensed to RNAx non-exclusive rights to IP covering the use... ...RNAx's research services business. RNAx will pay initial and annual license fees plus royalties to Ribopharma...
...RNAi companies Alnylam (Cambridge, Mass.) and Ribopharma (Kulmbach, Germany) merged to focus on developing therapeutics in... ...CEO of the combined company, and Ribopharma CEO Roland Kreutzer will be COO of the Ribopharma...
Ribopharma AG , Kulmbach, Germany Business: Chemistry Appointed: John Rossi, chair of the division of molecular biology at the Beckman Research Institute of the City of Hope Hospital; Ronald Plasterk, institute director of the Hubrecht Laboratory...
...return. Bunting also cited the return on Abingworth's 2003 seed investment of $2.2 million in Ribopharma AG... ...deal for an undisclosed amount. "We knew that Alnylam would be forced to merge with Ribopharma... ...it had the top IP- the most important patents in the space were held by Ribopharma...
...Alnylam business unit Ribopharma AG (Kulmbach, Germany) licensed to RNAx non-exclusive rights to IP covering the use... ...RNAx's research services business. RNAx will pay initial and annual license fees plus royalties to Ribopharma...
...RNAi companies Alnylam (Cambridge, Mass.) and Ribopharma (Kulmbach, Germany) merged to focus on developing therapeutics in... ...CEO of the combined company, and Ribopharma CEO Roland Kreutzer will be COO of the Ribopharma...
Ribopharma AG , Kulmbach, Germany Business: Chemistry Appointed: John Rossi, chair of the division of molecular biology at the Beckman Research Institute of the City of Hope Hospital; Ronald Plasterk, institute director of the Hubrecht Laboratory...
